Ukr.Biochem.J. 2024; Volume 96, Issue 6, Nov-Dec, pp. 47-55

doi: https://doi.org/10.15407/ubj96.06.047

Plasma gelsolin and matrix metalloproteinase-3 levels as diagnostic markers for psoriatic arthritis

04.12.2024   Uncategorized   No comments

Y. A. Zamzam1*, T. F. Mansour2, R. M. Salem3,
H. A. A. Hanout3, R. A. Mostafa1

1Department of Clinical Pathology, Faculty of Medicine, Tanta University, Egypt;
2Department of Internal Medicine (Rheumatology Unit), Faculty of Medicine, Tanta University, Egypt;
3Department of Rheumatology and Rehabilitation, Faculty of medicine, Tanta University, Egypt;
*e-mail: yosrazamzam@yahoo.com

Received: 18 June 2024; Revised: 10 August 2024;
Accepted: 21 November 2024; Available on-line: 17 December 2024

Recent studies have revealed a high prevalence of undiagnosed psoriatic arthritis (PsA) in patients with psoriasis. Diagnosis of psoriatic arthritis has proven challenging because the symptoms of the disease are nonspecific, rheumatoid factor is not detectable, and acute phase reactant levels may be normal. Therefore, identifying soluble biomarkers for diagnosing PsA in psoriasis patients may help in early diagnosis and proper management. The aim of the work was to evaluate plasma gelsolin and matrix metalloproteinase-3 (MMP-3) levels as potential markers for PsA. This case-control study included 25 healthy controls and 50 psoriasis patients, who were divided into 25 patients with psoriasis only and 25 patients with psoriatic arthritis. Plasma levels of gelsolin and MMP-3 were measured using ELISA. It was shown that patients with PsA had significantly lower gelsolin and significantly higher MMP-3 plasma levels compared to patients with psoriasis only. For detecting PsA, gelsolin and MMP-3 had sensitivity of 96% and specificity of 92 and 80% for each, respectively. Gelsolin level negatively while MMP-3 level positively correlated with such parameters­ as disease activity for psoriatic arthritis, composite psoriatic disease activity index, and inflammatory markers­ including high-sensitivity C-reactive protein and erythrocyte sedimentation rate. It was concluded that plasma gelsolin and MMP-3 levels could serve as potential biomarkers for diagnosing PsA and monitoring the disease progression in PsA patients.

Keywords: , , ,

References:

  1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. PubMed, PubMedCentral, CrossRef
  2. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. PubMed, CrossRef
  3. Azuaga AB, Ramírez J, Cañete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901. PubMed, PubMedCentral, CrossRef
  4. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970. PubMed, CrossRef
  5. López-Ferrer A, Laiz A, Puig L. Psoriatic arthritis. Med Clin (Barc). 2022;159(1):40-46. PubMed, CrossRef
  6. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273-2284. PubMed, CrossRef
  7. Kishimoto M, Deshpande GA, Fukuoka K, Kawakami T, Ikegaya N, Kawashima S, Komagata Y, Kaname S. Clinical features of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35(2):101670. PubMed, CrossRef
  8. Wirth T, Balandraud N, Boyer L, Lafforgue P, Pham T. Biomarkers in psoriatic arthritis: A meta-analysis and systematic review. Front Immunol. 2022;13:1054539. PubMed, PubMedCentral, CrossRef
  9. Maharaj AB, Adebajo A. Psoriatic arthritis in Africa. Clin Rheumatol. 2021;40(9):3411-3418. PubMed, CrossRef
  10. Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Similarities and differences. Joint Bone Spine. 2023;90(1):105469. PubMed, CrossRef
  11. Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatolog Treat. 2020;31(7):662-679. PubMed, CrossRef
  12. Bucki R, Levental I, Kulakowska A, Janmey PA. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci. 2008;9(6):541-551. PubMed, CrossRef
  13. Wittmann J, Dieckow J, Schröder H, Hampel U, Garreis F, Jacobi C, Milczarek A, Hsieh KL, Pulli B, Chen JW, Hoogeboom S, Bräuer L, Paulsen FP, Schob S, Schicht M. Plasma gelsolin promotes re-epithelialization. Sci Rep. 2018;8(1):13140. PubMed, PubMedCentral, CrossRef
  14. Piktel E, Levental I, Durnaś B, Janmey PA, Bucki R. Plasma gelsolin: indicator of inflammation and its potential as a diagnostic tool and therapeutic target. Int J Mol Sci. 2018;19(9):2516. PubMed, PubMedCentral, CrossRef
  15. Noren Hooten N, Mode NA, Kowalik E, Omoniyi V, Zonderman AB, Ezike N, DiNubile MJ, Levinson SL, Evans MK. Plasma gelsolin levels are associated with diabetes, sex, race, and poverty. J Transl Med. 2023;21(1):190. PubMed, PubMedCentral, CrossRef
  16. Feldt J, Schicht M, Garreis F, Welss J, Schneider UW, Paulsen F. Structure, regulation and related diseases of the actin-binding protein gelsolin. Expert Rev Mol Med. 2019;20:e7. PubMed, CrossRef
  17. Onuma T, Asare-Werehene M, Yoshida Y, Tsang BK. Exosomal plasma gelsolin is an immunosuppressive mediator in the ovarian tumor microenvironment and a determinant of chemoresistance. Cells. 2022;11(20):3305. PubMed, PubMedCentral, CrossRef
  18. Audley J, Gliniewicz EF, Zarember KA, Hong HS, Wald G, Kuhns DB, Kang E, Malech HL, Suffredini AF, Noveck RJ, Dinubile MJ, Levinson SL, Stossel TP, Gallin JI. Low plasma gelsolin concentrations in chronic granulomatous disease. Inflammation. 2021;44(1):270-277. PubMed, PubMedCentral, CrossRef
  19. Doddawad VG, Shivananda S, Kalabharathi HL, Shetty A, Sowmya S, Sowmya HK. Matrix metalloproteinases in oral cancer: a catabolic activity on extracellular matrix components. Biomed Biotechnol Res J. 2023;7(1):17-23. CrossRef
  20. Wan J, Zhang G, Li X, Qiu X, Ouyang J, Dai J, Min S. Matrix metalloproteinase 3: a promoting and destabilizing factor in the pathogenesis of disease and cell differentiation. Front Physiol. 2021;12:663978. PubMed, PubMedCentral, CrossRef
  21. Tuncer T, Kaya A, Gulkesen A, Kal GA, Kaman D, Akgol G. Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis. Adv Clin Exp Med. 2019;28(5):665-670. PubMed, CrossRef
  22. Chang M. Matrix metalloproteinase profiling and their roles in disease. RSC Adv. 2023;13(9):6304-6316. PubMed, PubMedCentral, CrossRef
  23. Lerner A, Neidhöfer S, Reuter S, Matthias T. MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(4):550-562. PubMed, CrossRef
  24. Zlatkovic-Svenda MI, Kerimovic-Morina D, Stojanovic RM. Psoriatic arthritis criteria evaluation: CASPAR and Modified CASPAR. Clin Exp Rheumatol. 2011;29(5):899-900. PubMed
  25. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441-1447. PubMed, CrossRef
  26. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale J D, Helliwell P, FitzGerald O. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70(2):272-277. PubMed, CrossRef
  27. Stober C. Pathogenesis of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35(2):101694. PubMed, CrossRef
  28. Zargari O, Leyli EK, Azimi SZ. Nail involvement in patients with psoriatic arthritis in Northern Iran. Autoimmune Dis. 2018;2018:4608490. PubMed, PubMedCentral, CrossRef
  29. Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55(3):131-135. PubMed, PubMedCentral, CrossRef
  30. Farrag DA, Asaad MK, Ghobrial CK. Evaluation of IL-34 in psoriasis and psoriatic arthritis patients: correlation with disease activity and severity. Egypt Rheumatolog. 2017;39(1):25-31. CrossRef
  31. Bartosińska J, Michalak-Stoma A, Juszkiewicz-Borowiec M, Kowal M, Chodorowska G. The assessment of selected bone and cartilage biomarkers in psoriatic patients from Poland. Mediators Inflamm. 2015;2015:194535. PubMed, PubMedCentral, CrossRef
  32. Mc Ardle A, Kwasnik A, Szentpetery A, Hernandez B, Parnell A, de Jager W, de Roock S, FitzGerald O, Pennington SR. Identification and evaluation of serum protein biomarkers that differentiate psoriatic arthritis from rheumatoid arthritis. Arthritis Rheumatol. 2022;74(1):81-91. PubMed, CrossRef
  33. Hsieh CH, Wang YC. Emerging roles of plasma gelsolin in tumorigenesis and modulating the tumor microenvironment. Kaohsiung J Med Sci. 2022;38(9):819-825. PubMed, CrossRef
  34. Gupta AK, Chopra BS, Vaid B, Sagar A, Raut S, Badmalia MD, Ashish, Khatri N. Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice. PLoS One. 2019;14(4):e0215717. PubMed, PubMedCentral, CrossRef
  35. Osborn TM, Verdrengh M, Stossel TP, Tarkowski A, Bokarewa M. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(5):R117. PubMed, PubMedCentral, CrossRef
  36. Esawy MM, Makram WK, Albalat W, Shabana MA. Plasma gelsolin levels in patients with psoriatic arthritis: a possible novel marker. Clin Rheumatol. 2020;39(6):1881-1888. PubMed, CrossRef
  37. Peng M, Jia J, Qin W. Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease. Neurosci Lett. 2015;595:116-121. PubMed, CrossRef
  38. Hu Y, Li H, Li WH, Meng HX, Fan YZ, Li WJ, Ji YT, Zhao H, Zhang L, Jin XM, Zhang FM. The value of decreased plasma gelsolin levels in patients with systemic lupus erythematosus and rheumatoid arthritis in diagnosis and disease activity evaluation. Lupus. 2013;22(14):1455-1461. PubMed, CrossRef
  39. Cretu D, Gao L, Liang K, Soosaipillai A, Diamandis EP, Chandran V. Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers. Arthritis Care Res (Hoboken). 2018;70(3):454-461. PubMed, CrossRef
  40. Geneva-Popova M, Popova-Belova S, Popova V, Chompalov K, Batalov A. Assessment of serum and synovial fluid MMP-3 and MPO as biomarkers for psoriatic arthritis and their relation to disease activity indices. Rheumatol Int. 2022;42(9):1605-1615. PubMed, CrossRef
  41. Hussein R, Aboukhamis I. Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis. Heliyon. 2023;9(3):e14008. PubMed, PubMedCentral, CrossRef
  42. Liang Z, Wang N, Shang L, Wang Y, Feng M, Liu G, Gao C, Luo J. Evaluation of the immune feature of ACPA-negative rheumatoid arthritis and the clinical value of matrix metalloproteinase-3. Front Immunol. 2022;13:939265. PubMed, PubMedCentral, CrossRef
  43. Michalak-Stoma A, Bartosińska J, Raczkiewicz D, Kowal M, Krasowska D, Chodorowska G. Assessment of selected matrix metalloproteinases (MMPs) and correlation with cytokines in psoriatic patients. Mediators Inflamm. 2021;2021:9913798. PubMed, PubMedCentral, CrossRef
  44. Waszczykowski M, Bednarski I, Narbutt J, Waszczykowska E, Lesiak A, Fabiś J. Interleukin-18, interleukin-20, and matrix metalloproteinases (MMP-1, MMP-3) as markers of psoriatic arthritis disease severity and their correlations with biomarkers of inflammation and turnover of joint cartilage. Postepy Dermatol Alergol. 2020;37(6):1001-1008. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.